Locations:
BristolSalary:
£113,565 to £150,569 a year pro rataDescription
Job summary
The post-holder will be responsible for the clinical management of patients under their care, and, in liaison with consultant colleagues, continuity of care when the postholder is absent.
The work of the Bristol Urological Institute (BUI) is delivered across two sites (Southmead Hospital and Weston General Hospital). The postholder is expected to deliver care on both sites according to their agreed job plan and the need of the service.
The post-holder will be expected to provide general/core urology service and be part of the non-muscle invasive bladder cancer team. They would be expected to contribute to fast track and diagnostic clinics. Support and mentoring will be provided where required.
As part of the service's target to expand theatre usage and improve theatre utilisation, the postholder, with other consultants, will provide flexible theatre cover as part of their weekly programmed activities aimed at providing extra capacity to meet cancer and waiting time targets.
The post-holder with contribute to the on-call consultant rota including out of hours cover on a pro rata basis.
Applicants should have a CCT or be within twelve months of achieving this at the date of interview or be listed on the GMC's specialist register to be eligible for application for a substantive post. CESR applicants are welcome and must have their CESR in place at the time of interview.
Main duties of the job
The post-holder will provide high-quality, evidence-based urological care to patients referred to the Bristol Urological Institute, with particular responsibility for general/core urology and the management of non-muscle invasive bladder cancer. They will undertake outpatient clinics, diagnostic and surveillance cystoscopy, day-case and inpatient procedures, and elective operating appropriate to their agreed job plan and areas of expertise. The post-holder will work closely with colleagues across the BUI to ensure effective continuity of care and timely access to appropriate investigation and treatment.
Closing date: 1 November 2026
